Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CARsgen Cleared to Start China Trials of CAR-T Liver Cancer Treatment

publication date: Jan 29, 2019

Shanghai's CARsgen Therapeutics announced that China's NMPA cleared the IND for its CAR-T treatment aimed at GPC3-positive solid tumors. The company, which is focused on CAR-T drug development, claims its CAR-T candidate is the first to be cleared in China for solid tumor cancers. Glypican-3 (GPC3) is overexpressed in liver cancer, which will be a target of the candidate, along with squamous lung cancer. CARsgen expects to start a similar US trial by the end of 2019. The company now has five CAR-T therapies in trials. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital